Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics

Osama Chahrour, Anna Meljon, Diego Cobice

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The development of suitable analytical tools is required to study the stability, manufacturability and bio-performance of peptide conjugate therapeutics. Mass spectrometric analysis provides essential knowledge for understanding and building the critical quality attributes and regulatory specifications of peptides. The purpose of this chapter is to provide an overview/update of mass spectrometric techniques (e.g. ion stripping and isotopic labelling) that are employed for the analytical characterization and quantitation of peptides and their conjugates such as PEGylated peptides and antibody–drug conjugates. Advances in high-resolution mass spectrometry (HRMS) have considerably increased the quality of analytical data on antibody–peptide drug conjugates [e.g. average drug-to-antibody ratio (DAR), drug loading distribution, unconjugated drug and impurity characterization via peptide mapping] that can be used for product and process development, lot release and stability testing. Similarly, the quality of PEGylated peptides can be evaluated via qualitative and quantitative mass spectrometric analysis to ensure that the PEGylated therapeutics have the desired properties such as molecular mass and polydispersity. In addition, relative or absolute mass spectrometric-based quantitation of peptides/peptide conjugates is very useful for assessing stability, label claim and batch-to-batch variability. Different strategies exploiting stable isotope labelling and isotope dilution are possible, each having specific strengths and weaknesses. Inductively coupled plasma mass spectrometry (ICP-MS) has recently emerged as a complementary technique to the previous methods allowing absolute protein quantification using suitable elemental-based tags.
LanguageEnglish
Title of host publication Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls
Place of PublicationUK
PublisherRoyal Society of Chemistry
Chapter10
Pages343-380
Number of pages38
Editionfirst
ISBN (Electronic) 978-1-78801-869-2, 978-1-78801-644-5
ISBN (Print) 978-1-78801-433-5
DOIs
Publication statusE-pub ahead of print - 20 Aug 2019

Publication series

NameDrugs Discovery

Fingerprint

Quality control
Peptides
Pharmaceutical Preparations
Isotopes
Labeling
Antibodies
Inductively coupled plasma mass spectrometry
Molecular mass
Polydispersity
Dilution
Mass spectrometry
Labels
Impurities
Ions
Specifications
Testing
Proteins

Cite this

Chahrour, O., Meljon, A., & Cobice, D. (2019). Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics. In Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls (first ed., pp. 343-380). (Drugs Discovery). UK: Royal Society of Chemistry. https://doi.org/10.1039/9781788016445-00343
Chahrour, Osama ; Meljon, Anna ; Cobice, Diego. / Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics. Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls . first. ed. UK : Royal Society of Chemistry, 2019. pp. 343-380 (Drugs Discovery).
@inbook{08430122e0894a468fe01db35a8e0fb7,
title = "Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics",
abstract = "The development of suitable analytical tools is required to study the stability, manufacturability and bio-performance of peptide conjugate therapeutics. Mass spectrometric analysis provides essential knowledge for understanding and building the critical quality attributes and regulatory specifications of peptides. The purpose of this chapter is to provide an overview/update of mass spectrometric techniques (e.g. ion stripping and isotopic labelling) that are employed for the analytical characterization and quantitation of peptides and their conjugates such as PEGylated peptides and antibody–drug conjugates. Advances in high-resolution mass spectrometry (HRMS) have considerably increased the quality of analytical data on antibody–peptide drug conjugates [e.g. average drug-to-antibody ratio (DAR), drug loading distribution, unconjugated drug and impurity characterization via peptide mapping] that can be used for product and process development, lot release and stability testing. Similarly, the quality of PEGylated peptides can be evaluated via qualitative and quantitative mass spectrometric analysis to ensure that the PEGylated therapeutics have the desired properties such as molecular mass and polydispersity. In addition, relative or absolute mass spectrometric-based quantitation of peptides/peptide conjugates is very useful for assessing stability, label claim and batch-to-batch variability. Different strategies exploiting stable isotope labelling and isotope dilution are possible, each having specific strengths and weaknesses. Inductively coupled plasma mass spectrometry (ICP-MS) has recently emerged as a complementary technique to the previous methods allowing absolute protein quantification using suitable elemental-based tags.",
author = "Osama Chahrour and Anna Meljon and Diego Cobice",
year = "2019",
month = "8",
day = "20",
doi = "10.1039/9781788016445-00343",
language = "English",
isbn = "978-1-78801-433-5",
series = "Drugs Discovery",
publisher = "Royal Society of Chemistry",
pages = "343--380",
booktitle = "Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls",
address = "United Kingdom",
edition = "first",

}

Chahrour, O, Meljon, A & Cobice, D 2019, Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics. in Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls . first edn, Drugs Discovery, Royal Society of Chemistry, UK, pp. 343-380. https://doi.org/10.1039/9781788016445-00343

Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics. / Chahrour, Osama; Meljon, Anna; Cobice, Diego.

Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls . first. ed. UK : Royal Society of Chemistry, 2019. p. 343-380 (Drugs Discovery).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics

AU - Chahrour, Osama

AU - Meljon, Anna

AU - Cobice, Diego

PY - 2019/8/20

Y1 - 2019/8/20

N2 - The development of suitable analytical tools is required to study the stability, manufacturability and bio-performance of peptide conjugate therapeutics. Mass spectrometric analysis provides essential knowledge for understanding and building the critical quality attributes and regulatory specifications of peptides. The purpose of this chapter is to provide an overview/update of mass spectrometric techniques (e.g. ion stripping and isotopic labelling) that are employed for the analytical characterization and quantitation of peptides and their conjugates such as PEGylated peptides and antibody–drug conjugates. Advances in high-resolution mass spectrometry (HRMS) have considerably increased the quality of analytical data on antibody–peptide drug conjugates [e.g. average drug-to-antibody ratio (DAR), drug loading distribution, unconjugated drug and impurity characterization via peptide mapping] that can be used for product and process development, lot release and stability testing. Similarly, the quality of PEGylated peptides can be evaluated via qualitative and quantitative mass spectrometric analysis to ensure that the PEGylated therapeutics have the desired properties such as molecular mass and polydispersity. In addition, relative or absolute mass spectrometric-based quantitation of peptides/peptide conjugates is very useful for assessing stability, label claim and batch-to-batch variability. Different strategies exploiting stable isotope labelling and isotope dilution are possible, each having specific strengths and weaknesses. Inductively coupled plasma mass spectrometry (ICP-MS) has recently emerged as a complementary technique to the previous methods allowing absolute protein quantification using suitable elemental-based tags.

AB - The development of suitable analytical tools is required to study the stability, manufacturability and bio-performance of peptide conjugate therapeutics. Mass spectrometric analysis provides essential knowledge for understanding and building the critical quality attributes and regulatory specifications of peptides. The purpose of this chapter is to provide an overview/update of mass spectrometric techniques (e.g. ion stripping and isotopic labelling) that are employed for the analytical characterization and quantitation of peptides and their conjugates such as PEGylated peptides and antibody–drug conjugates. Advances in high-resolution mass spectrometry (HRMS) have considerably increased the quality of analytical data on antibody–peptide drug conjugates [e.g. average drug-to-antibody ratio (DAR), drug loading distribution, unconjugated drug and impurity characterization via peptide mapping] that can be used for product and process development, lot release and stability testing. Similarly, the quality of PEGylated peptides can be evaluated via qualitative and quantitative mass spectrometric analysis to ensure that the PEGylated therapeutics have the desired properties such as molecular mass and polydispersity. In addition, relative or absolute mass spectrometric-based quantitation of peptides/peptide conjugates is very useful for assessing stability, label claim and batch-to-batch variability. Different strategies exploiting stable isotope labelling and isotope dilution are possible, each having specific strengths and weaknesses. Inductively coupled plasma mass spectrometry (ICP-MS) has recently emerged as a complementary technique to the previous methods allowing absolute protein quantification using suitable elemental-based tags.

UR - http://www.scopus.com/inward/record.url?scp=85072264737&partnerID=8YFLogxK

U2 - 10.1039/9781788016445-00343

DO - 10.1039/9781788016445-00343

M3 - Chapter

SN - 978-1-78801-433-5

T3 - Drugs Discovery

SP - 343

EP - 380

BT - Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls

PB - Royal Society of Chemistry

CY - UK

ER -

Chahrour O, Meljon A, Cobice D. Mass Spectrometric Analysis for the Quality Control of Peptide Conjugate Therapeutics. In Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls . first ed. UK: Royal Society of Chemistry. 2019. p. 343-380. (Drugs Discovery). https://doi.org/10.1039/9781788016445-00343